Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 5:52 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 4,606 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo (single-dose) Clear all
Completed Phase 1 Interventional

A Study to Assess the Effect of AZD5634 on Mucociliary Clearance, Safety, Tolerability and Pharmacokinetic Parameters in Patients With Cystic Fibrosis

NCT02950805
View directory record Official record
Conditions
Pulmonary/Respiratory Diseases
Interventions
Placebo, AZD5634
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 60 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
3
States / cities
Birmingham, Alabama • Baltimore, Maryland • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 13, 2018 · Synced Oct 10, 2026, 5:52 PM EDT
Terminated Phase 4 Interventional Results available

Use of Transdermal Clonidine in Trauma Patients

NCT01139996
View directory record Official record
Conditions
Delirium
Interventions
Clonidine, Placebo
Drug
Lead sponsor
Memorial Health University Medical Center
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Savannah, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 10, 2026, 5:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Clinical Trial of an Alphavirus Replicon Vaccine for Cytomegalovirus (CMV)

NCT00439803
View directory record Official record
Conditions
Cytomegalovirus Infections
Interventions
AVX601, Placebo
Biological
Lead sponsor
AlphaVax, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 10, 2008 · Synced Oct 10, 2026, 5:52 PM EDT
Completed Phase 2 Interventional Results available

Study of Efficacy and Safety of IV VIS410 Plus Oseltamivir Versus Oseltamivir in Hospitalized Adults With Influenza A

NCT03040141
View directory record Official record
Conditions
Influenza A
Interventions
Low dose of VIS410, High dose of VIS410, Placebo
Drug
Lead sponsor
Visterra, Inc.
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
21
States / cities
Tucson, Arizona • Stanford, California • St. Petersburg, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2022 · Synced Oct 10, 2026, 5:52 PM EDT
Completed Phase 4 Interventional Results available

A Study That Will Compare the Effect of Two Drugs on Participants With Low Bone Mass and a Recent Hip Fracture

NCT00887354
View directory record Official record
Conditions
Osteoporosis
Interventions
Teriparatide, Risedronate, Placebo, Calcium, Vitamin D
Drug · Dietary Supplement
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
50 Years and older
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
6
States / cities
Fort Lauderdale, Florida • New Port Richey, Florida • Orlando, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2019 · Synced Oct 10, 2026, 5:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of DZD2269 in Healthy Adult Participants

NCT04932005
View directory record Official record
Conditions
Healthy Volunteers
Interventions
DZD2269, placebo
Drug
Lead sponsor
Dizal Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Secaucus, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 1, 2022 · Synced Oct 10, 2026, 5:52 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Enhancing Panic and Smoking Reduction Treatment With D-Cycloserine

NCT01944423
View directory record Official record
Conditions
Nicotine Addiction, Panic Attack
Interventions
d-cycloserine, Pill Placebo, Nicotine replacement therapy, Panic and Smoking Reduction Treatment
Drug · Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years to 65 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 19, 2021 · Synced Oct 10, 2026, 5:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Staccato Prochlorperazine Single Dose PK Study

NCT00610727
View directory record Official record
Conditions
Migraine
Interventions
Prochlorperazine 0.5 mg IV over 5 sec, Inhaled prochlorperazine 0.625 mg, Inhaled prochlorperazine 1.25 mg, Inhaled prochlorperazine 2.5 mg, Inhaled prochlorperazine 5 mg, Inhaled prochlorperazine 10 mg, Inhaled placebo, Prochlorperazine 10 mg IV over 5 sec
Drug
Lead sponsor
Nova Pneuma Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 10, 2026, 5:52 PM EDT
Withdrawn Phase 4 Interventional

Cannabidiol for Treatment Resistant Depression

NCT04732169
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Active study drug ( oral CBD), matching placebo
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 19, 2021 · Synced Oct 10, 2026, 5:52 PM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

A Study to Learn About the Safety and Immune Responses of RSVpreF in Older Adults

NCT07819097
View directory record Official record
Conditions
Adult, Healthy Participants
Interventions
RSVpreF, Placebo
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
60 Years and older
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
14
States / cities
Scottsdale, Arizona • Lake Forest, California • Riverside, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 10, 2026, 5:52 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Adults With Previously Untreated Chronic Lymphocytic Leukemia

NCT01980888
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Idelalisib, Bendamustine, Rituximab, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
311 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
23
States / cities
Fullerton, California • La Jolla, California • Santa Maria, California + 20 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2018 · Synced Oct 10, 2026, 5:52 PM EDT
Completed Phase 1 Interventional

A Study of MDX-1106 to Treat Patients With Hepatitis C Infection

NCT00703469
View directory record Official record
Conditions
Hepatitis C
Interventions
MDX1106-02, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
7
States / cities
Anaheim, California • San Francisco, California • Springfield, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2010 · Synced Oct 10, 2026, 5:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Diindolylmethane in Preventing Cancer in Healthy Volunteers

NCT00784394
View directory record Official record
Conditions
Healthy, no Evidence of Disease
Interventions
diindolylmethane, placebo, pharmacological study, laboratory biomarker analysis, quality-of-life assessment
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 29, 2016 · Synced Oct 10, 2026, 5:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Safety of Intravenous Artesunate

NCT00292929
View directory record Official record
Conditions
Malaria, Malaria, Cerebral
Interventions
Intravenous artesunate
Drug
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 26, 2016 · Synced Oct 10, 2026, 5:52 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Acute Treatment Trial in Adult Subjects With Migraines

NCT03872453
View directory record Official record
Conditions
Migraine
Interventions
Zavegepant, Zavegepant matching placebo, Intranasal Aptar Pharma Unit Dose System
Drug · Device
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
2,154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
82
States / cities
Mobile, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 75 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2023 · Synced Oct 10, 2026, 5:52 PM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age

NCT07300839
View directory record Official record
Conditions
COVID-19, SARS-COV-2 Infection
Interventions
BNT162b2 Vaccine, Placebo
Biological
Lead sponsor
BioNTech SE
Industry
Eligibility
50 Years to 64 Years
Enrollment
5,240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
196
States / cities
Anniston, Alabama • Athens, Alabama • Birmingham, Alabama + 148 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 10, 2026, 5:52 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate Safety, Tolerability and Immune Response in Adults Allergic to Peanut After Receiving Intradermal or Intramuscular Administration of ASP0892 (ARA-LAMP-vax), a Single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Plasmid Vaccine

NCT02851277
View directory record Official record
Conditions
Peanut Allergy
Interventions
ASP0892 Intradermal, ASP0892 Intramuscular, Placebo Intradermal, Placebo Intramuscular
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
8
States / cities
Little Rock, Arkansas • Mountain View, California • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2024 · Synced Oct 10, 2026, 5:52 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Efficacy of Recombinant Bovine Lactoferrin (rbLf) in Iron Regulation

NCT06428357
View directory record Official record
Conditions
Exercise Performance
Interventions
Recombinant Bovine Lactoferrin, Bovine Milk-Derived Lactoferrin, Placebo
Dietary Supplement
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 42 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Oct 10, 2026, 5:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single and Multiple Ascending Doses, Relative Bioavailability, Food Effect, and Drug-Drug Interaction Study of NX-5948 in Healthy Volunteers

NCT06717269
View directory record Official record
Conditions
Healthy Volunteer
Interventions
NX-5948, Esomeprazole, Placebo, Famotidine, Midazolam, Digoxin, Rosuvastatin, Quinidine
Drug
Lead sponsor
Nurix Therapeutics, Inc.
Industry
Eligibility
19 Years to 55 Years
Enrollment
223 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
2
States / cities
Phoenix, Arizona • Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 10, 2026, 5:52 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease

NCT00877383
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Indacaterol 150 μg, Tiotropium 18 μg, Placebo to indacaterol
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
1,142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
116
States / cities
Anniston, Alabama • Birmingham, Alabama • Jasper, Alabama + 102 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2011 · Synced Oct 10, 2026, 5:52 PM EDT
Completed Phase 3 Interventional Results available

The Approach Open Label Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Participants With Familial Chylomicronemia Syndrome

NCT02658175
View directory record Official record
Conditions
Familial Chylomicronemia Syndrome, Lipoprotein Lipase Deficiency, Hyperlipoproteinemia Type 1
Interventions
Volanesorsen
Drug
Lead sponsor
Akcea Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
8
States / cities
Huntington Beach, California • San Francisco, California • Boca Raton, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2021 · Synced Oct 10, 2026, 5:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7503 in Healthy Participants

NCT05143905
View directory record Official record
Conditions
Safety, Tolerability, Pharmacokinetics, Healthy Participants
Interventions
AZD7503, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Feb 19, 2025 · Synced Oct 10, 2026, 5:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of LY3871801 in Healthy Asian and Non-Asian Participants

NCT05960851
View directory record Official record
Conditions
Healthy
Interventions
LY3871801, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Jan 10, 2024 · Synced Oct 10, 2026, 5:52 PM EDT
Completed Phase 3 Interventional Results available

Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC

NCT00806819
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Nintedanib (BIBF1120), Pemetrexed, B12, dexamethasone (or corticosteroid equivalent), placebo, Folic Acid
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
718 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
40
States / cities
Downy, California • Fountain Valley, California • Fullerton, California + 37 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2017 · Synced Oct 10, 2026, 5:52 PM EDT